There is a strong demand for the identification of new biomarkers in colorectal cancer (CRC)
diagnosis. Among all liquid biopsy analysts, cell-free circulating DNA (cfDNA) is probably …

Tumor heterogeneity is a major challenge and the root cause of resistance to treatment. Still,
the standard diagnostic approach relies on the analysis of a single tumor sample from a …

PURPOSE Novel sensitive methods for early detection of relapse and for monitoring
therapeutic efficacy may have a huge impact on risk stratification, treatment, and ultimately …

The increased availability of data and recent advancements in artificial intelligence present
the unprecedented opportunities in healthcare and major challenges for the patients …

Background Neoadjuvant chemoradiotherapy (nCRT) plus surgery is a standard treatment
for locally advanced oesophageal cancer. With this treatment, 29% of patients have a …

Purpose: Response to preoperative chemo-radiotherapy (CRT) varies. We assessed
whether circulating tumor DNA (ctDNA) might be an early indicator of tumor response or …

PURPOSE Current diagnostic methods to determine programmed death 1 (PD-1) receptor
and its ligand (PD-L1)/PD-1 immunotherapy (immune checkpoint inhibitor [ICI]) efficacy in …

Response evaluation for cancer treatment consists primarily of clinical and radiological
assessments. In addition, a limited number of serum biomarkers that assess treatment …

Characterization, diagnosis, and treatment of colorectal cancers (CRC) is difficult due to
limited biopsy information, impracticality of repeated biopsies, and cancer biomarker …

Colorectal cancer (CRC) is frequently diagnosed at an advanced stage of the disease, the
pathogenesis of which is influenced by genetic and epigenetic events. Circulating tumor …